Last reviewed · How we verify
Cardioversion of Atrial Fibrillation — Treatment Landscape & Competitive Intelligence
3 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Tikosyn | DOFETILIDE | Pfizer | Antiarrhythmic [EPC] | Potassium voltage-gated channel subfamily H member 2 | 1999-01-01 | |
| Corvert | IBUTILIDE | Pfizer | Antiarrhythmic | Potassium voltage-gated channel subfamily H member 2 | 1995-01-01 | |
| Quinidine Gluconate | QUINIDINE SULFATE | Eli Lilly | Antiarrhythmic | Muscarinic acetylcholine receptor M2 | 1950-01-01 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Pfizer · 2 drugs in Cardioversion of Atrial Fibrillation
- · 1 drug in Cardioversion of Atrial Fibrillation
- Eli Lilly · 1 drug in Cardioversion of Atrial Fibrillation
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Cardioversion of Atrial Fibrillation:
- Cardioversion of Atrial Fibrillation treatment updates — RSS
- Cardioversion of Atrial Fibrillation treatment updates — Atom
- Cardioversion of Atrial Fibrillation treatment updates — JSON
Cite this brief
Drug Landscape (2026). Cardioversion of Atrial Fibrillation — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/cardioversion-of-atrial-fibrillation. Accessed 2026-06-10.
Related
- Cardioversion of Atrial Fibrillation full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing